SuanFarma-Header SuanFarma-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshReset Filter
              refresh Reset Filter
              price-trend All Drugs in Dev.

              Product Type

              Companies

              Iontas

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              Post An Enquiry Post An Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth

              Mediterranean Congress of Chemical

              Participation Not Confirmed

              Update your events

              IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies

              Lead Product(s): Neutralizing antibodies

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: FairJourney Biologics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2021

              Details:

              The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalized COVID-19 patients, have identified potent neutralizing antibodies with distinct mechanisms of action.

              Exscientia

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              Post An Enquiry Post An Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth

              Mediterranean Congress of Chemical

              Participation Not Confirmed

              Update your events

              Exscientia Receives $4.2M Grant From Gates Foundation to Identify New Targets and Lea...

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

              Deal Size: $4.2 million Upfront Cash: Undisclosed

              Deal Type: Funding December 10, 2020

              Details:

              Through this partnership, Exscientia will use its Centaur Biologist™ platform to apply domain-specific implementations of knowledge graphs and deep learning algorithms to a diverse wealth of biological data.